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This paper integrates a wider case study on PharmCo, a pharmaceutical company that is currently 
building a strategy to entry the hospital generics market. 
The research aims to investigate what United Kingdom (UK) hospitals key decision makers perceive as 
value when purchasing generic pharmaceuticals, and how the company can co-create value with these 
customers. 
The outcome provides a customer value analysis model and value propositions recommendations so 
PharmCo can achieve comp etitive advantage in the market.  
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1. Introduction 
This paper integrates a wider case study on PharmCo, one of the biggest global pharmaceutical 
companies that is building a strategy to entry the generics sector on 16 European markets. 
The research aim is to investigate what United Kingdom (UK) hospitals key decision makers perceive as 
value when purchasing generic pharmaceuticals, and how PharmCo can co-create value with these 
customers, developing customized solutions to best offer value propositions. 
The key characteristic in the market assessed is its proximity to the economic definition of perfect 
competition. Fighting commoditization on the hospital segment implies a strategy that emphasizes 
PharmCo’s expertise on offering additional services (Berghman et al, 2006). As stated by Woodruff 
(1997), the next major source of competitive advantage will probably come from outward efforts 
towards the customers, as testified by many companies’ calls to compete in terms of creating superior 
customer value. 
To pursue the forementioned goal, this paper is structured to firstly, provide a review on main academic 
literature on value co-creation together with practical approaches to identify value elements and build 
value propositions. Secondly, to explain the research and methodology conducted and thirdly, to detail 
the research findings, main implications and recommendations so PharmCo can co-create value with 
hospitals. In addition, a discussion on research limitations and opportunites for further development is 
provided. 
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2. Literature Review 
Vargo and Lusch (2004) introduced the Service Dominant (SD)-logic in marketing and set the concept of 
customer value co-creation as a required integrative component on firms’ strategies so for them to 
provide differentiated service. They framed the concept as a desired outcome of some of the new 
marketing dominant logic propositions but have not explored practical approaches on how companies 
must proceed to achieve it. 
Understanding what customers value in different contexts and what customer value creation strategies 
are more or less appropriate in particular environments is central to marketing strategy and marketing 
thought (Smith and Colgate, 2007, p. 9). In today’s competitive business markets, suppliers are 
continuously challenged to anticipate rather than follow changes in customer value and buyers often 
seek innovative suppliers that are offering new value concepts or total solution packages (Berghman et 
al, 2006, p. 969). 
In the generic pharmaceutical hospital market, knowledge of what constitutes value to the customer is a 
critical factor and, according to Anderson et al (1993), can be thought of as the cornerstone of business 
market management. Companies need to identify current offerings and learn how these can be 
enhanced to provide value to customers; in order words, there is a call for understanding what drivers 
create value for customers so as to build a competitive advantage (Lapierre, 2000, p. 122). 
To define the path to competitive advantage through the product and service attributes for generic 
drugs, the following topic (2.1) will initially discuss main academic views on customer value and the 
process of value co-creation. Moving forward, topic 2.2 will look into practical approaches to capture 
buyers’ perceived value, and the base requirements so PharmCo can design the value propositions to its 
customers. 
 
2.1. Customer value and value co-creation 
Ulaga (2001) looks at customer value from three different perspectives: 
• The buyer’s perspective focus on assessing how suppliers can create value for their customers 
and how this is perceived as superior in comparison to competition (through products and 
services); 
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• The seller’s perspective consists on the management of customer equity; 
• The buyer-seller perspective states that value co-creation comes from a joint effort of suppliers 
and customer.  
The buyer-seller perspective description given by Ulaga is the most common approach and is linked to 
the concept of value-creating networks, where firms come together to co-create customer value 
(Kothandaraman and Wilson, 2001; Cova and Salle, 2008). Although an important path to co-create 
value, the buyer-seller network view tends to be restrictive towards other possibilities of value co-
created offers besides the association of the buyers and suppliers with other firms in a favourable 
network. 
According to Kothandaraman and Wilson (2001), PharmCo would have to associate itself with other 
companies in order to achieve superior customer value. Based on Prahalad and Hamel’s (1990) core 
competence concept, they state that a single company would hardly have all the skills required to add 
significant value to the market offering. Although Vargo and Lusch (2004, 2008b) uses the core 
competence’s theory as one of the basis for their work, they do not restrict the ability of companies to 
co-create value through exploring their networks as this is mentioned as a beneficial, not an obligatory 
movement.   
In an alternative view, value co-creation could be seen as an interaction of firms where both parties are 
able to increase their effectiveness. The buyer by receiving a value offer that in fact improves its 
operations (e.g.: safety, revenues, time to market) and the supplier by either increasing its customer 
loyalty or by increasing its profitability (either by gaining new loyal customers that also see value on the 
co-created value propositions or by adding new solutions that will increase the purchasing requests by 
this buyer). In this case, partnerships involving other companies do not have to exist so as to accomplish 
value co-creation. 
Berghman et al (2006, p. 963) gives relevance to the network approach, but it broadens the topic, stating 
that “new value creation capacity in business market is determined by marketing knowledge absorptive 
capacity as well as organizational and supply chain/network competences … moreover, identifying which 
(combinations of) competences lead to high new value creation capacity will help companies aiming at a 
market driving strategy, to focus on the right ‘drivers’”. 
Based on the definition that the creation of value depends on the ability to deliver high performance on 
the benefits that are important to the customer (Kothandaraman and Wilson, 2001, p. 381), it can be 
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said that if PharmCo has the core competence or/and the capability to use relationship skills to 
understand and respond to required adaptations and improvements on its value offers, it is able to co-
create value with its customers.  
For Möller and Törrönen (2003), value offers created by suppliers can have three different goals, 
classified into efficiency, effectiveness and network dimensions. Based on Vargo and Lusch’s (2004) 
study, efficiency is built-in effectiveness. This last “refers to an actor’s ability to invent and produce 
solutions that provide more value to markets (customers) than existing offers” (Möller and Törrönen, 
2003, p. 112). Although the development of products and processes through partnerships would reduce 
costs and difficulties involved in the path of value creation, a single supplier is still able to produce new 
effective solutions together with its customer (Möller and Törrönen, 2003). 
Having ascertained that a company can co-create value either by concentrating all required skills to co-
create value propositions and/or by complementing its capabilities by engaging into a value network, the 
next topic moves on to review practical approaches that can be used o identify what hospitals perceive 
as value and how to co-create value propositions by enhancing product and service attributes. 
 
2.2. Customer value analysis and value propositions 
“Just as there is no commonly accepted definition of customer value, there is no definitive 
conceptualization, framework, or typology of customer value. Some attempts have been made, but 
there is no consensus and so far, no ‘universal’ structure or process to be followed.” (Smith and Colgate, 
2007, p. 8) 
Lindgreen et al. (2009) offer a practical framework on how to identify the appropriate value offers to key 
decision-influencers in the purchasing process. Their main contribution revolve around the development 
of a comprehensive model for understanding business customer’s value needs after an initial stage of 
gaining insight of business customers’ decision-making unit and purchasing process. Because the buying 
process mapping was already performed in the group section of this project, this study directly focus on 
the identification of perceived value for hospitals. 
Although Lindgreen et al. (2009) model is based on the innovative medical industry equipment, the 
process approach and frameworks can be applied for the generic pharmaceutical sector because of the 
similarities in between the business customer structures – both industries work in the health care sector 
and have as customers the hospital segment with a structured purchasing process. 
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The initial step in order to understand customer value is to identify possible attributes and their relative 
importance and benefits to key decision makers. For this stage, Lindgreen et al. (2009) suggest that a list 
with possible product, service and supplier attributes needs to be designed through direct customers’ 
feedback. Because of the breath of scope required to cover these three attributes, the project excludes 
the supplier approach.  
The second step to build the customer value analysis model is to detect, within the product and service 
related attributes, the most relevant ones with the purpose of linking and categorising them into value 
elements, according to common benefits they bring. Lindgreen et al. (2009) rank these values according 
to their degree of importance, measured by percentage levels given by the decision-influencers 
responses.  Some of the sub-categories created by the authors can be used directly on PharmCo’s 
project, such as ‘return on investment’, product related, and ‘ease of use’, service related. Other 
groupings must be defined according to the qualitative research conducted on the course of the project. 
After identifying and categorising value elements crossed with their provided benefits it is possible to 
recognize the main constrains for hospital members and develop value propositions. This mapping of 
customer needs works as guidance so PharmCo can decide upon the value propositions to be created 
within the limitations of its profit margin. It is true that an entry level stage requires higher investments 
and some offerings will assure recognition of the company as strategic supplier; but an evaluation of 
sacrifices and benefits from both sides of the buyer-supplier interaction also has to be deployed for value 
co-creation.  
Other approaches have been developed to assess value and to help on the creation of value 
propositions. Despite the difference on terminologies and framework structure, all the works include an 
understanding and feedback from customers in order to customize offers. Some constructive approaches 
to PharmCo’s case are described below. 
Sharma, Krishnan and Grewal (2001), present a framework to value creation that highlights the 
marketing activities that enhance value generation by business marketers. They divide the process into 
three major sub-processes: technology delivery, product delivery, and customer delivery process.  
Improvements in the technology delivery sub-process would include innovations in the hospital 
pharmacist systems that would increase their stock management or even add speed to their ordering 
process. The author gives an example of research and development results that, in PharmCo’s case, 
could bring handling and safety improvements to the hospital users.  
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The product delivery process is concerned with adding value through product development and delivery 
tasks, to make sure that products meet customer requirements and internal commitments on quality, 
cost, delivery, and speed-to-market (Sharma, Krishnan and Grewal, 2001). An example given by the 
authors is 3M’s cross-functional teams that work to build up close relationships with their leading-edge 
customers to develop breakthrough products. They understand their processes and what they perceive 
as value and they work on creating the solutions. 
The customer delivery process generates value through effective supply-chain management, covering 
sales, fulfilment, and service of products (Sharma, Krishnan and Grewal, 2001, p. 398). 
Rao’s (2009) approach is directly aimed at the pharmaceutical industry. It states that, to deliver targeted 
differentiation on its industry of product similarity, a combination of factors must be studied such as 
hospitals current prescriber and payer targets as well as the specific benefits seen in the product by 
these prescribers, the value of competitors products in the eyes of prescribers, patients and payers, and 
the overall cost-to-overall benefit perception of the product in the minds of its users. In PharmCo’s case, 
as in most markets in Europe the current prescriber and the payer target are usually the same person,  
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3. Methodology 
This paper design follows the same case study qualitative research explained in the main part of the 
project.  Although, the central question is narrower, focusing only in the UK instead of the broad target 
of 16 European hospital markets. 
The research explores what hospitals perceive as value to generic pharmaceuticals and what value 
propositions PharmCo can create to become differentiated and preferred on their purchasing decision 
making process. The propositions have a restricted focus on product and service attributes factors.  
The evidence collected to answer the research questions raised (Yin, 2009) follows a qualitative 
approach with in-depth interviews within pharmacists involved in the buying process across hospitals in 
the UK plus representatives of the National Health Service (NHS) Commercial Medicines Unit (CMU), 
which is a main health agency in the country responsible, amongst other tasks, for pharmaceutical 
purchases.  
Market research secondary data with a total 30 UK interviewers conducted by a sponsored PharmCo 
consultancy is the base of the work. So as to verify and gather more in depth information within these 
groups, a further primary qualitative research was conducted. In total, 9 additional in-depth interviews 
were carried out in England including respondents from 4 different NHS trusts and one representative of 
the CMU. These interviews attested the results of the former interviews and were valuable to improve 
the detail level on the hospital environment and their requirements for safety and detailed product 
enhancement factors. Although more interviews were initially planned, during the interviewing process 
course, information became redundant.  
The content of the secondary data included questions related to understanding the main characteristics 
of hospitals operations, financials and major issues faced by customers, complaints on supplier 
partnerships and complements to innovative offerings, improvements ideas on the product and service 
level.  Also, market research provided by PharmCo included descriptions of specific customer 
preferences regarding different attributes and their willingness to pay a price premium for these.  
In order to gather knowledge to evaluate the secondary data, and to perform the additional interviews a 
desk based research was conducted to pursue knowledge on pharmaceutical related issues such as 
molecule components, handling and administration hospital techniques, UK drugs guidelines and 
regulatory framework, competitor product and services characteristics etc.  
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Furthermore, a comprehensive knowledge of PharmCo’s contextual setting was required and interviews 
with 3 members of the Generics Marketing and Commercial Division was conducted. Here, the main 
enquiry focus was to understand the current operations, products, hospital offerings for branded 
products, company background etc. At this stage, an understanding of goals and offer limitations was 
essential to build the research propositions and to focus the work. This was also valuable because 
PharmCo provided access to numerous sector reports that, together with the in-depth conversations, 
helped to build awareness of the pharmaceutical market as a whole. 
  
3.1. Building the customer value analysis model 
As mentioned in the literature review, Lindgreen et al. (2009) customer value analysis model is the 
selected methodology to both identify customer needs and co-create value propositions.  
The data collected was evaluated with the goal of building a list of possible value elements relating to 
product and service attributes for the UK hospitals.  Through a process of combination, recombination 
redefinition and adjustment to different categories, these attributes were summarised. Firstly, all 
attributes with similar meaning were condensed into a unique one. Secondly, this process was revised in 
order to assure the degree of importance of each attribute and to guarantee that no crucial one was 
dismissed.  That was necessary because the initial list of attributes was long and repetitive. The selected 
attributes were then linked to potential benefits and divided into sub-categories within the product and 
service main categories. 
After the value elements were categorised, it was possible to conduct an evaluation to identify the 
constraints for hospitals to improve their effectiveness. In order to illustrate the degree of importance 
and to facilitate the interpretation of the data, the main categorised value elements were given 
representative percentages to indicate the level of interest each respondent placed on it. The highest the 
percentage, the highest the consensus amongst interviewers that the value is important and a key 
potential benefit for their hospitals (influencer in the purchasing decision making process).   
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4. Findings - Customer Value Elements  
The initial step towards the construction of PharmCo’s value proposition is the identification of the key 
decision makers in the hospital segment for generics (Lindgreen et al., 2009), also categorized as the 
current prescriber and payer target (Rao, 2009). As researched in the group part of this project, in the 
UK, the direct purchasing decision makers are pharmacists on the procurement department of the NHS 
CMU. These groups are influenced by regional trusts pharmacists (specially the head/chief pharmacist), 
which are responsible for initially evaluating suppliers, placing new drug orders as well as dealing the 
daily/weekly stock replenishment. Also, for some specialty drugs/therapeutic areas (e.g.: oncology) these 
trusts can run the tenders themselves. Therefore, the key decision makers referred to in the findings 
below involve interviewed members of the CMU Pharmacy Division, Head Pharmacists from UK NHS 
trusts and some staff pharmacist members involved in the process of ordering the generic drugs.  
As explained in the methodology, following the main purpose proposed by Lindgreen et al. (2009) model, 
possible product and service attributes were identified from the data gathered (see appendix 7.1.) and 
translated into value elements. In total 73 attributes were identified and reduced to 34, being 18 for the 
product category and 17 for the service category. Under each of the two main categories, six value 
elements sub-groups were created based on their benefits similarity. These are shown in table 1, which 
includes the information on the intensity interviewers placed in each attribute (e.g.: plastic vials), 
represented by percentages in the column of level of interest.  
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Table 1: Benefits and value elements (Adapted from Lindgreen et al., 2009) 
 
Under the product-related category, three sub-categories of value elements were created: return on 
investment, hospital user differentiation and safety features differentiation. Beneath the service 
category, the other three sub-group of benefits include ‘ease of use’, service support, and supply chain 
management. The level of interest indicates how much decision makers consider each attribute and 
correspondent benefit when making the purchase. As an example, the initial product price was 
mentioned by all respondents and was unanimity in terms of importance. These product and service 
value elements sub-categories will be detailed and better discussed in topics 4.1 and 4.2 below. 
 
4.1. Product-related value elements 
In total, interviewers listed 36 attributes related to product, which were condensed to 18. The first value 
element sub-category, return on investment, includes 6 of these attributes and refers to the need of 
fulfilling technical and clinical drugs criteria as well as economic needs. In most cases, decision makers 
showed concerns towards the efficacy level of generics in comparison to branded versions and also 
mentioned problems with the range of indications of generic drugs. In simple words they expressed their 
preference to have a generic product that assures the quality and coverage of symptoms at the same 
level the branded version does. To achieve a better return on investment, they would expect the 
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medications to be cheaper as well as to match brand quality and characteristics.  A statement from UK 
pharmacists from 2 different public hospitals supports this finding: 
“We are always looking at three parameters in that decision: efficacy, safety and cost effectiveness. So 
we have to demonstrate that the generic product is as effective as the branded product. This is done in 
the lab (dissolution, etc.) and we would also look for evidence in terms of clinical practice. Also we look in 
between generics from different companies. Those things being acceptable, at the end of the day, if 
everything else is comparable, then costs would be determining factor.” 
“Providing there are no important pharmaco-kinetic differences between the two it's left to the pharmacy 
to provide the best product that is most affordable and most effective. So if the generic product is good 
and cheaper than a branded one, there are no reasons for us to stick with the branded product.”  
When launching a generic drug, a supplier develops and approves the formulation following the original 
branded version. Because it is a “copy” of a tested medication, no further clinical trials are required and 
the generic is assumed to work in the same conditions as the original drug. Complains from respondents 
relate to the fact that some of the specialty generics, especially injectables, have a lower efficacy level. In 
some cases this can be translated on the drug having lesser effect on the patient, on a longer time to act 
on the patient or a shorter time than required of drug effect, etc.  
Besides the monetary/clinical (price/efficacy) related aspects, the highest number of mentions 
concerned innovative features to speed the operational handling and administration process for users 
(hospital pharmacists) on top of increased safety aspects for both hospital users and patients.  
The second sub-category under the product one relates to innovative value elements and the benefits 
enclosed on ready to use (RTU) drug formulations. The main advantages raised by respondents are time 
and cost savings but these improvements also represent a great contribution to more safety. Because of 
requirements on injectables preparation, these features were mentioned to be particularly valued for 
oncologic products (see appendix 7.2 for further comments on RTU). Some of these innovations already 
exist and are commercialised in a branded product level, although others are still to be developed. The 
main attributes mentioned by respondents and their potential benefits are described on table 2 below. 
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Table 2: RTU benefits from grouped value element attributes 
 
“Excellent. I think the technology improvements are great, ready to use. The needleless reconstitution, 
those sorts of things. They are reducing the risks associated with packaging and labelling. That sort of 
things are great.” (Pharmacist, public hospital) 
Overall respondents expressed the need for continuous development of different packaging/labelling 
and dosages in order to adapt to new needs raised by new pathologies and to contribute to the overall 
safety of delivery of care, as exemplified by some respondents’ statements below. 
“Most important: Clearer labelling which reduces the risk of misunderstanding what is contained in the 
vial and reduce the risk of incorrectly issued medicines” (Purchasing pharmacist, private hospital) 
“All of these product aspects are taken into account during the tender adjudication process. Labelling 
being the most important one after price and clinical efficacy.” (CMU Pharmacist) 
The safety features sub-group that would represent a differentiator for PharmCo include improvements 
on generics labelling, substitution of glass ampoules to plastic vials for handling and administration of 
injectables, needle stick prevention, provision of allergen, and latex and preservative free formulations. 
Although colour coding on external packaging was mentioned, many respondents positioned against it. 
The pros and cons mentioned by respondents relating to all safety aspects are summarized in table 3. 
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Table 3: Safety benefits from grouped value element attributes 
 
 
4.2. Service-related elements 
The three main value elements extracted from constraints described by interviewers relate to ease of 
use of generic drugs, service support, and supply chain management support. Overall, 37 service related 
attributes were listed and summarized to 16.  
The sub-group with the ‘ease of use’ value element relates to the benefits brought by product 
innovations but it shows the importance place on speeding the user routine product handling process. 
New drugs, different dosages or complex instructions require longer handling times and risk of confusion 
and product waste. Information on how to deal with these products or even ‘on the job’ training is 
welcomed by respondents.  Also, features mentioned in the topic above can contribute not only for 
safety and cost effectiveness points, but also to speed the time of hospital user (nurse, pharmacist or 
clinician) when dealing with the patient, bringing benefits for both sides.  
“This is the way forward … The fewer steps needed for preparation the better. Many people looking into 
this problem, trying to work out how to reduce the number of steps the nurses are doing in the treatment 
rooms prior to the administration.” (Chief Pharmacist, public hospital) 
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A unanimity complain from all key decision makers questioned was the lack of support from suppliers 
concerning scientific, clinical and safety data from drugs, especially by the time of their introduction to 
the hospital. Respondents emphasized the absence of generic suppliers’ (in general) direct channel with 
a full range of information on their product, and expressed high dissatisfaction level and perception of 
this as a lack of commitment from generic pharmaceutical companies. This service is linked to value 
elements listed on other sub-categories mentioned above. The biggest dissatisfaction relates to suppliers 
who only provide the minimum tender requirement data and do not provide clinical data on a 
continuous base.  
Some related cases when customer support was required, mainly to clarify doubts on the product, refers 
not only to difficulties on reaching a supplier contact/channel, but also achieving the solution/answer to 
the matter, as evidenced below. Complains about strictly commercial supplier teams and lack of 
products technical/scientific knowledge are common and hospital members said that they would benefit 
from access to drug specialists.  
“It is always difficult to access generic suppliers. They close the deal and disappear, and it is really hard to 
get any information on drugs. And this is something we do need.” (Chief Pharmacist, UK Hospital)  
When questioned about the benefits of drug sampling and staff training some were positive but the 
majority did not consider this as a strong value element. Also, for generic drugs in the UK, hospitals 
affirmed to not require a designated sales representative. Some even mentioned this as a negative 
aspect because a supplier member presence in the hospital, when not required, would have no value 
added. In their words, they would prefer to have a direct channel to call or access when support is 
needed. 
“It is complicated, the sales guy comes always in the worst times and never respond when you actually 
need ... But usually they only have these for branded products. Not many visits from generic companies ... 
It would be good to have a phone to call right when we have questions.” (Pharmacist, UK Hospital) 
Finally, supply chain issues were constantly mentioned. Former problems with unreliable suppliers raised 
pharmacists concerns towards terms of delivery and conformity to contract volume and delivery dates 
negotiated. In addition to agreed values, members mentioned the benefits of suppliers providing 
emergency deliveries and a service that provide drugs directly into some patient houses, specific for 
some therapeutic areas.  
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Also related to supply chain value elements, stock management was mentioned as a major concern. 
Some respondents highlighted that the introduction of a 2D bar on packaging combined with a bar 
coding equipment, would fit into the ongoing trend of ‘informatisation’ of the whole process of drug 
administration, ordering and stocking. This value was set as beneficial (but not essential) so pharmacists 
can keep track of stocks, act anticipatory, and tie drug usage to departments and individual patients.   
At last, some respondents mentioned the value of suppliers helping hospitals on waste management. 
Although this could represent cost savings to the hospitals, key decision makers did not seem 
enthusiastic about the feature and mentioned that eventual support would not be central for 
differentiating generic pharmaceuticals companies, as evidenced by the statement below. 
“Yes, all these factors are considered with some being more important than others i.e. labelling is the 
most important. Waste management is not a major as we operate a safe disposal system in the hospital 
anyway.” (Head Pharmacist, UK public hospital) 
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5. Customer Value Analysis Model and Implications for PharmCo 
5.1. Customer value analysis model 
After consolidating and evaluating hospital value elements and having in hands the basic needs and main 
constrains key decision maker’s face, it is possible to place this data in the customer value analysis model 
proposed by Lindgreen et al. (2009). The model places the 6 value elements sub-categories (product and 
service related) from table 1, as illustrated in figure 1. 
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The model starts by listing hospitals basic needs, which includes three main aspects that were identified 
in the main part of the project, which integrates this individual study. In the figure (1), these basic needs 
are the motivational aspects to hospital key decision makers to engage in the relational exchange with 
generic pharmaceutical suppliers.  
The three product value elements/sub-categories (return on investment, hospital user differentiation, 
and service features differentiation) as well as the three service ones (‘ease of use’, service support, and 
supply chain management) are the base to the identification of the customers constraints, and the 
middle part of the figure, the called cognitive level, is the final result of the model.  
The model goes from the product consequence aspects towards behavioural aspects. It initially 
approaches value elements linked to product attributes and then move to service benefits and other 
differential solutions. In the original model from Lindgreen et al. (2009), the figure would include 
another category of attributes exploring supplier value elements, which moves even deeper into 
intangible benefits. Although, as aforementioned, this was not part of the project scope and it not 
included on the set of interviews and complementary research conducted.  
The cognitive level describes all major constraints for hospitals beyond the basic needs. This is the 
outcome of the process of gathering and analysing data for the sub-categorisation of product and service 
value elements, explored and detail in the findings topic (4). At this stage, considering the targeted 
members take in consideration business and operational affairs for purchasing choice (always related to 
clinical aspects), the major constraints were listed under these headings and, for each problem, a 
possible strategy was appointed.  
By proposing a strategy to address hospital constrains, based on the identified value elements, PharmCo 
is building value propositions. This concept is aligned with Vargo and Lusch’s (2004) ideas as well as 
Berghman et al (2006), Smith and Colgate (2007), Lapierre (2000) and others mentioned in the literature 
review. 
The outcomes from the proposed model are aligned with the value creation framework presented by 
Sharma, Krishnan and Grewal (2001) in terms of the technology, product, and customer delivery 
processes explained in the literature review section of this paper.  Innovation/technology enhancement 
relates to proposed benefits from sub-categories such as safety features differentiation and ‘ease of 
use’. Product delivery process is linked to the increase in hospital effectiveness with the supply of RTU 
    22  
 
generic drugs. At last, value elements from the supply chain management sub-category match the 
proposed customer delivery process.  
A closer look at the strategy proposed as solutions to the main constraints is better explained on topic 6 
below. 
 
5.2. Implications for PharmCo and the value propositions 
Overall, respondents placed positive views over PharmCo’s entrance on the market and assured that 
new generic drug development by the company, including a wide range of indications would surely 
create value for the hospital.  As shown in figure 1, other ‘strategies’ were identified as means so the 
company can co-create value with hospitals. 
Besides some obvious measures such sustaining a competitive price, discount on volumes and dosage 
options, quick market authorisation and generic drug launching right after the end of patent, PharmCo 
can differentiate itself by offering a highly requested element not provided by any other generic supplier, 
which involves creating channels that provide scientific, clinical and safety related information. Since 
there is little request for generic supplier physical presence in UK hospitals, the company can develop an 
‘encyclopedia’ website and/or a direct hotline for the whole country.   
Other value elements raised can be used to create value propostions. This includes investments on 
product attributes in order to increase safety aspects, to provide RTU formulations and to bring service 
effectiveness to hospital users as well as supply chain related benefits. 
In order to offer value propositions linked to supply chain management value element sub-category, 
PharmCo might need to engage on partnerships with whoselares who can provide the emergency supply 
or even the service that deliver drugs to patient residences. Also, if the decision upon adopting the 2D 
Bar coding labelling is taken, the company might need to work with the hospital and a third partner to 
monitor stock levels and provide automatic replenisment. This last value proposition offer demands 
further evaluation on implementation/operational requirements. A lack of bar coding machinery in 
hospitals and a high cost of system development would have to be put against the benefits the offer 
would bring to the relationship.  
Some of the value propositions suggested are simple and require lower investments from PharmCo, 
considering the company has already an infra-structure settled for its branded division (e.g.: scientific, 
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medical and safety data availability). Particular product innovations can even bring savings to PharmCo 
at the same time that brings value to customers. The change from glass ampoules to plastic vials can be 
combined with a partnership with a third company for collection of used vials and recycling process. 
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6. Conclusions and summary of main recommendations 
6.1. Conclusions 
The research of this paper aimed to provide PharmCo with an understanding of the UK hospital decision 
makers needs to improve thier generic pharmaceutical service. To enter the generics market in Europe, 
the company must evaluate the value propositions identified here and summarised on the following 
topic (7.2) as well as further assess supplier attributes towards more intangible benefits.  
In addition, PharmCo the company must use the customer value analysis outcome to evaluate wether if 
it can co-create value with the hospitals based on its unique skills or if  ought to search for partnerships 
in conjunction to its buyers to enhance value throught the usage of networks. 
 
6.2. Summary of main recommendations 
A combination of the value propositions/actions (figure 1 ‘strategies’) recommended below will help to 
bring a supplier differentiated status for Pharmco: 
• Offer competitive prices/discounts and assure drug presence on reimbursement list; 
• Guarantee clinical efficacy, desired range of indications and guidelines conformity; 
• Invest on RTU innovative formulations; 
• Improve/secure safety on product handling and adminstration; 
• Offer training for new complex or information; 
• Invest on channels with full range of data to support customers; 
• Constant forecast and follow up of demands. If too costly to manage, engage in partnership with 
wholesaler to assure fulfilment of hospital needs; 
• If overall costs for the company not too high, implement a patient direct supply service (can think of 
partnerships or additional contract value added with premium price charged).  
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7. Research limitations and further research  
7.1. Project research limitations 
The majority of the interviews was conducted by a secondary consultancy and the initial findings came 
from their interpretation of data. Further primary qualitative research conducted reach similar results 
but, although strong consideration was taking on criticizing gaps on the secondary market research, it is 
possible that an initial access to results before conduction of the interviews could have bias the 
interpretation and analysis of results. 
Also, although intensive research was conducted to map the hospital behaviour and preferences on 
generic pharmaceuticals, a lack of background experience in the sector could have suppressed more 
advanced findings.  
 
7.2. Suggestions for further research in the topic area 
The study of supplier attributes could bring valuable findings to the creation of new PharmCo offerings. 
Aspects relating to brand awareness, trust and commitment constructs and other relationship related 
elements are part of the process of value creation and were not explored in this paper.  
The value network approach to co-create value can be better explored with more detailed research on 
PharmCo’s core capabilities and limitations. Also, further study over PharmCo’s current partnerships for 
the branded division could represent an opportunity to bring superior value to hospitals with the 
replication of proper value propositions to the generic business.  
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8. Appendix 
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8.2. Ready to Use Formulations 
Some products can provide both professionals and non-professionals with safe, convenient and easy-to-
use systems for reconstituting and administering injectable drugs. These are called ready to use (RTU) 
formulations systems and can be provided either as a total packaged solution or as components for 
specialized use. 
Many RTU solutions are already a common practice in the market and others are still on trial phases but 
much more can be invented to help increase hospitals effectiveness (Reynolds, 2006). These products 
are extremely welcomed for the preparation of injectables that requires handling and administration of 
different drug components. 
An example of a RTU formulation is given below. 
 
8.2.1. About Acto Vials reconstitution systems 
“Act-O-Vial” is a dual-compartment vial system that allows reconstitution of a sterile, injectable drug by 
pressing down on the plastic cap. This vial contains water for injection (WFI) in the upper chamber and a 
freeze-dried pharmaceutical preparation in the lower chamber. The dual-chamber design offers users 
the convenience of not having to handle an additional vial to draw the WFI from. It enables a unique, 
sterile drug delivery system that offers an outstanding option for otherwise unstable, injectable 
formulations. It’s just another example of possibilities of complex sterile manufacturing technology 
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